THEROXIDIL Drug Patent Profile

Which patents cover Theroxidil, and when can generic versions of Theroxidil launch?

Theroxidil is a drug marketed by Pure Source and is included in two NDAs.

The generic ingredient in THEROXIDIL is minoxidil. There are eight drug master file entries for this compound. Eighty-one suppliers are listed for this compound. Additional details are available on the minoxidil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Theroxidil

A generic version of THEROXIDIL was approved as minoxidil by WATSON LABS on March 3^rd, 1987.

Summary for THEROXIDIL

US Patents:	0
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for THEROXIDIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pure Source	THEROXIDIL	minoxidil	SOLUTION;TOPICAL	078176-001	Nov 9, 2007		OTC	No	No
Pure Source	THEROXIDIL	minoxidil	SOLUTION;TOPICAL	076239-001	Aug 24, 2004		OTC	No	No

Overview of THEROXIDIL Investment and Fundamentals

Last updated: February 3, 2026

THEROXIDIL is a topical drug primarily used for treating androgenic alopecia (pattern hair loss). It contains minoxidil, a vasodilator approved by the FDA initially for hypertension, later repurposed for hair regrowth. Its global brand and generic sales generate significant revenue, with broad market penetration.

Market Fundamentals

• Market Size and Growth: The global hair growth market is valued at approximately $4.2 billion as of 2022. It is expected to grow annually at 5-6%, driven by rising awareness and aging populations. Minoxidil-based products account for an estimated 25-30% of this market.[1]

• Competitive Landscape: The primary market players include Johnson & Johnson (Rogaine), Dr. Reddy's, and Cipla. Generics dominate due to patent expirations; branded variants command premium prices.

• Patent and Regulatory Status: Minoxidil formulations in topical solutions and foams face patent expirations, exposing market share to generics. However, formulation patents in specific dosing devices or combination therapies may provide temporary exclusivity.

• Pricing and Revenue: In the U.S., a month's supply of THEROXIDIL typically retails for $30-$50. Estimated global revenues from THEROXIDIL are approximately $1 billion annually, primarily in North America, Europe, and Asia-Pacific.

Investment Scenario Analysis

1. Product Portfolio and Development Pipeline

• The core product, THEROXIDIL topical solution, enjoys mature market share. R&D efforts focus on:
  • Combination therapies (e.g., minoxidil with finasteride analogs).
  • Novel delivery systems enhancing absorption.
  • Extended-release formulations aiming for less frequent application.

2. Patent Expiry and Market Entry Barriers

• Patents on active formulations expired in key markets; generic competition limits pricing power.
• Ongoing patent applications on delivery devices and combination therapies offer potential competitive edges.

3. Regulatory Challenges and Approvals

• Post-approval, future formulations require submissions to FDA/EMA. Regulatory delays can impact time-to-market and revenue projections.

4. Market Penetration Strategies

• Expansion into emerging markets (e.g., India, China) where hair restoration is popular.
• Collaborations with local distributors to reduce costs and boost sales.

5. Financial Performance and Risks

• Revenue growth relies on maintaining market share amid rising generic competition.
• Cost structures benefit from existing manufacturing processes, but R&D and regulatory costs persist.
• Revenue volatility if market penetration slows or new competitors emerge.

6. Pricing and Reimbursement

• Price sensitivity exists; reimbursement in certain regions could influence consumer uptake.

Risks and Opportunities

• Risks: Patent erosion, intense competition, regulatory rejections for new formulations, potential safety concerns leading to label restrictions.
• Opportunities: Combination therapies with patent life extensions, growth in emerging markets, innovation in delivery technology.

Summary

Investing in THEROXIDIL involves balancing mature product income streams with patent cliff risks. Future growth depends on innovation, market expansion, and navigating regulatory landscapes. The competitive environment favors early adopters of novel delivery systems and combination formulations.

---

Key Takeaways

• The global hair regrowth market is stable but highly competitive with significant generic pressure.
• THEROXIDIL’s core market faces patent expirations, but innovation areas present growth opportunities.
• Expansion into emerging markets offers notable upside.
• Revenue stability relies on maintaining market share and product differentiation.
• R&D investments in novel delivery and combination therapies are critical for long-term competitiveness.

---

FAQs

1. How long before THEROXIDIL faces generic competition fully?
   Patent expirations in major markets typically occur within the next 2-3 years, after which generic competition can substantially reduce prices and market share.

2. What are the primary drivers of growth for THEROXIDIL?
   Expanding to emerging markets, innovation in delivery mechanisms, and combination therapy development are key drivers.

3. How does regulatory approval affect the investment outlook?
   Delays or rejections in regulatory submissions can hinder new product launches, impacting revenue growth and valuation.

4. What is the potential impact of biosimilars or alternative formulations?
   As formulations evolve, biosimilars for new delivery methods may challenge existing products, pressuring prices and margins.

5. How significant is the risk of safety concerns affecting market acceptance?
   Safety concerns, especially related to systemic absorption or adverse effects, could lead to label restrictions and decline in consumer confidence.

---

References

[1] MarketWatch. "Hair Growth Market Size, Share & Trends." 2022.